Dashboard
Manage Tickers

REGNREGENERON PHARMACEUTICALS, ...

Nasdaq regeneron.com


$ 1,051.44 $ -17.72 (-1.66 %)    

Thursday, 27-Jun-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.07 $ 2.09 (0.44 %)
DIA $ 391.62 $ 0.38 (0.1 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.14 (0.15 %)
GLD $ 215.08 $ 2.50 (1.18 %)
$ 1069.16
$ 1,073.28
$ 1,050.33 x 200
$ 0.00 x 0
$ 1,047.31 - $ 1,073.54
$ 684.81 - $ 1,081.17
524,084
na
123.06B
$ 0.54
$ 31.90
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-05-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-06-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-07-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-08-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-07-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-07-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-08-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-11-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

first-inhaled-copd-therapy-in-over-2-decades---fda-approves-verona-pharmas-first-commercial-product
First Inhaled COPD Therapy In Over 2 Decad...
06/27/2024 13:49:19

The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary dis...

canaccord-genuity-maintains-buy-on-regeneron-pharmaceuticals-maintains-1152-price-target
Canaccord Genuity Maintains Buy on Regener...
06/27/2024 13:41:35

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $1152 price...

Core News & Articles
Regeneron, Sanofi Present Phase 3 Trial Fo...
06/26/2024 21:34:07

The trial showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvement...

looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity
Looking At Regeneron Pharmaceuticals's Rec...
06/25/2024 19:03:51

argus-research-maintains-buy-on-regeneron-pharmaceuticals-raises-price-target-to-1170
Argus Research Maintains Buy on Regeneron ...
06/25/2024 12:29:10

Argus Research analyst Jasper Hellweg maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price targ...

regeneron-pharmaceuticals-approach-to-improve-quality-of-weight-loss-has-merit-goldman-sachs
Regeneron Pharmaceuticals' Approach To Imp...
06/24/2024 18:36:01

Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing signific...

the-analyst-verdict-regeneron-pharmaceuticals-in-the-eyes-of-13-experts
The Analyst Verdict: Regeneron Pharmaceuti...
06/24/2024 16:01:12

rbc-capital-reiterates-outperform-on-regeneron-pharmaceuticals-maintains-1229-price-target
RBC Capital Reiterates Outperform on Regen...
06/24/2024 14:07:12

RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and maintains $1229 ...

5-biotech-stocks-with-key-catalysts-this-week-merck-intellia-verona-and-more
5 Biotech Stocks With Key Catalysts This W...
06/24/2024 08:51:47

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

100-invested-in-this-stock-20-years-ago-would-be-worth-10000-today
$100 Invested In This Stock 20 Years Ago W...
06/20/2024 18:30:14

jp-morgan-maintains-overweight-on-regeneron-pharmaceuticals-raises-price-target-to-1150
JP Morgan Maintains Overweight on Regenero...
06/17/2024 14:20:13

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price targ...

regenerons-dupixent-copd-sales-to-reach-20b-by-2026-analyst-sees-larger-addressable-market
Regeneron's Dupixent COPD Sales To Reach $...
06/13/2024 13:39:02

Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.

rbc-capital-maintains-outperform-on-regeneron-pharmaceuticals-raises-price-target-to-1229
RBC Capital Maintains Outperform on Regene...
06/12/2024 11:53:45

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price ...

peering-into-regeneron-pharmaceuticalss-recent-short-interest
Peering Into Regeneron Pharmaceuticals's R...
06/11/2024 20:45:11

Core News & Articles
Regeneron Anticipates Obesity Drug Trial D...
06/11/2024 12:23:38

- Goldman Sachs Conference

Core News & Articles
Regeneron, Sanofi Report FDA Approval Of K...
06/11/2024 11:02:06

goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upside
Goldman Sachs Optimistic About Regenxbio's...
06/07/2024 18:30:54

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

whats-going-on-with-fibrogen-stock-tuesday
What's Going On With FibroGen Stock Tuesday?
06/04/2024 18:27:03

FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational...

competitor-analysis-evaluating-regeneron-pharmaceuticals-and-competitors-in-biotechnology-industry
Competitor Analysis: Evaluating Regeneron ...
06/04/2024 15:00:55

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)